Optimi Health produces psilocybin capsules for Phase II MDD study

Phase 2Psilocybin capsulesPositive

AI Analysis

Summary

Optimi Health has completed production and quality release of 5mg psilocybin capsules for a Health Canada-authorized Phase II MDD trial and commercial supply to Australia.

Clinical Trial Data

Phase

Phase II

Importance:3/10

Sentiment:

0.30

psilocybinMDDmanufacturingHealth CanadaAustraliaPhase 2

Related Companies

$OPTHF

Read the original article

Published by Clinical Trials Arena on September 24, 2026 9:42 AM

Read Original